Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis

Marjolein Mijnders, Bertrand Kleizen, Ineke Braakman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Pharmacological intervention to treat the lethal genetic disease cystic fibrosis has become reality, even for the severe, most common folding mutant F508del CFTR. CFTR defects range from absence of the protein, misfolding that leads to degradation rather than cell-surface localization (such as F508del), to functional chloride-channel defects on the cell surface. Corrector and potentiator drugs improve cell-surface location and channel activity, respectively, and combination therapy of two correctors and a potentiator have shown synergy. Several combinations are in the drug-development pipeline and although the primary defect is not repaired, rescue levels are reaching those resembling a cure for CF. Combination therapy with correctors may also improve functional CFTR mutants and benefit patients on potentiator therapy.
Original languageEnglish
Pages (from-to)83-90
Number of pages8
JournalCurrent Opinion in Pharmacology
Volume34
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint

Dive into the research topics of 'Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis'. Together they form a unique fingerprint.

Cite this